Subanesthetic Ketamine Improves Depressive Symptoms in Critically Ill Adults

Depressive symptoms in the intensive care unit often complicate the clinical course of critically ill patients, yet traditional antidepressants typically require weeks to achieve therapeutic efficacy [1]. While subanesthetic doses of ketamine, an N-methyl-D-aspartate receptor antagonist (a drug that blocks a specific glutamate receptor involved in neural signaling), have demonstrated rapid antidepressant effects in outpatient psychiatric populations, its utility in the acute critical care setting remains less defined [2, 3]. Meta-analytic data from 20 randomized controlled trials indicate that ketamine achieves its maximal effect at 24 hours (standardized mean difference -0.89; 95% confidence interval -1.24 to -0.53; p < 0.00001), with clinical benefits persisting for up to seven days [4]. Clinicians face significant challenges in managing psychological distress in the intensive care unit, where hemodynamic stability is paramount and the risk of delirium or adverse drug interactions is high [5]. Current guidelines for the intensive care unit emphasize multimodal strategies for pain and agitation, but specific interventions for acute depressive symptoms are often limited to supportive care [6, 5]. A new retrospective analysis now examines the clinical impact of intravenous ketamine on mood and hemodynamic parameters within this vulnerable patient population.